Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Rating of Buy by Analysts

Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Rating) have received an average recommendation of “Buy” from the twelve research firms that are presently covering the firm, Marketbeat Ratings reports. Eleven investment analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12 […]

Related Keywords

Canada ,Stifel Nicolaus ,Simonn Pimstone ,Ian Mortimer ,Analyst Recommendations For Xenon Pharmaceuticals ,Cantor Fitzgerald ,Xenon Pharmaceuticals ,Xenon Pharmaceuticals Inc ,Institutional Investors Weigh In On Xenon Pharmaceuticals ,Xenon Pharmaceuticals Trading ,Advisors Asset Management Inc ,Cubist Systematic Strategies ,Royal Bank ,News Ratings For Xenon Pharmaceuticals Daily ,Insider Activity At Xenon Pharmaceuticals ,Nasdaq ,Wells Fargo Company ,Needham Company ,Get Rating ,Marketbeat Ratings ,Director Simon ,Asset Management ,Systematic Strategies ,Pharmaceuticals Inc ,Xenon Pharmaceuticals Daily ,